Search

Within Europe and North America the integration of environmental concerns into agriculture has become a domain almost exclusively defined by public policy. In this paper it is contended that we are currently witnessing a new direction in attempts to reconcile agricultural production and environmental protection, in which the market is playing an increasingly important role. The paper takes as its focus the rapidly expanding number of what are termed ‘market-oriented initiatives for environmentally sustainable food production’ (MOIs), in which the incentive for food producers to manage the environment positively comes directly through the market. The number of MOIs, in both Europe and North America, has proliferated recently, although some have been established for many years. However, both older and newer forms of these MOIs appear to be the focus of a new rural development, food quality, and sustainable farming agenda. In an attempt to make a contribution to this emergent debate, this paper sets out to address the extent to which these MOIs are capable of contributing to the development of more environmentally sustainable food production. In this paper we consider the drivers of this new approach, review the various types of MOI that are emerging in both Europe and North America, and examine the different approaches to environmental management that MOIs adopt. The paper also offers a reflection upon the potential contribution of MOIs to the delivery of environmental goods in food production and the implications of this for public sector approaches. [ABSTRACT FROM AUTHOR]

Purpose: EURAMOS-1, an international randomized controlled trial, investigated maintenance therapy with pegylated interferon alfa-2b (IFN-α-2b) in patients whose osteosarcoma showed good histologic response (good response) to induction chemotherapy., Patients and Methods: At diagnosis, patients age ≤ 40 years with resectable high-grade osteosarcoma were registered. Eligibility after surgery for good response random assignment included ≥ two cycles of preoperative MAP (methotrexate, doxorubicin, and cisplatin), macroscopically complete surgery of primary tumor, < 10% viable tumor, and no disease progression. These patients were randomly assigned to four additional cycles MAP with or without IFN-α-2b (0.5 to 1.0 μg/kg per week subcutaneously, after chemotherapy until 2 years postregistration). Outcome measures were event-free survival (EFS; primary) and overall survival and toxicity (secondary)., Results: Good response was reported in 1,041 of 2,260 registered patients; 716 consented to random assignment (MAP, n = 359; MAP plus IFN-α-2b, n = 357), with baseline characteristics balanced by arm. A total of 271 of 357 started IFN-α-2b; 105 stopped early, and 38 continued to receive treatment at data freeze. Refusal and toxicity were the main reasons for never starting IFN-α-2b and for stopping prematurely, respectively. Median IFN-α-2b duration, if started, was 67 weeks. A total of 133 of 268 patients who started IFN-α-2b and provided toxicity information reported grade ≥ 3 toxicity during IFN-α-2b treatment. With median follow-up of 44 months, 3-year EFS for all 716 randomly assigned patients was 76% (95% CI, 72% to 79%); 174 EFS events were reported (MAP, n = 93; MAP plus IFN-α-2b, n = 81). Hazard ratio was 0.83 (95% CI, 0.61 to 1.12; P = .214) from an adjusted Cox model., Conclusion: At the preplanned analysis time, MAP plus IFN-α-2b was not statistically different from MAP alone. A considerable proportion of patients never started IFN-α-2b or stopped prematurely. Long-term follow-up for events and survival continues.